DE3404193C2 - - Google Patents

Info

Publication number
DE3404193C2
DE3404193C2 DE3404193A DE3404193A DE3404193C2 DE 3404193 C2 DE3404193 C2 DE 3404193C2 DE 3404193 A DE3404193 A DE 3404193A DE 3404193 A DE3404193 A DE 3404193A DE 3404193 C2 DE3404193 C2 DE 3404193C2
Authority
DE
Germany
Prior art keywords
compound
formula
compounds
antipsychotic
mol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE3404193A
Other languages
German (de)
English (en)
Other versions
DE3404193A1 (de
Inventor
Davis L. Evansville Ind. Us Temple Jun.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of DE3404193A1 publication Critical patent/DE3404193A1/de
Application granted granted Critical
Publication of DE3404193C2 publication Critical patent/DE3404193C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE19843404193 1983-02-07 1984-02-07 5-fluor-pyrimidin-2-yl-piperazin-verbindung, verfahren zu ihrer herstellung und pharmazeutische mittel Granted DE3404193A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46427583A 1983-02-07 1983-02-07

Publications (2)

Publication Number Publication Date
DE3404193A1 DE3404193A1 (de) 1984-08-09
DE3404193C2 true DE3404193C2 (el) 1987-06-11

Family

ID=23843239

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19843404193 Granted DE3404193A1 (de) 1983-02-07 1984-02-07 5-fluor-pyrimidin-2-yl-piperazin-verbindung, verfahren zu ihrer herstellung und pharmazeutische mittel

Country Status (5)

Country Link
JP (1) JPS59148780A (el)
DE (1) DE3404193A1 (el)
FR (1) FR2540499B1 (el)
GB (1) GB2139217B (el)
MY (1) MY8800109A (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748240A (en) * 1987-04-03 1988-05-31 American Home Products Corporation Psychotropic bicyclic imides
US5239847A (en) * 1991-06-12 1993-08-31 Samsung Electronics Co., Ltd. Agitator for a washing machine
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3398151A (en) * 1966-02-01 1968-08-20 Mead Johnson & Co Azaspirodecanediones and azaspiroundecanediones
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method

Also Published As

Publication number Publication date
FR2540499B1 (fr) 1986-09-26
GB2139217A (en) 1984-11-07
FR2540499A1 (fr) 1984-08-10
GB2139217B (en) 1986-07-09
JPS59148780A (ja) 1984-08-25
JPH0319233B2 (el) 1991-03-14
MY8800109A (en) 1988-12-31
GB8403102D0 (en) 1984-03-07
DE3404193A1 (de) 1984-08-09

Similar Documents

Publication Publication Date Title
DE3248160C2 (de) 2-[4-[(4,4-Dialkyl-2,6-piperidindion-1-yl)-butyl]-1-piperazinyl]pyrimidine, Verfahren zu ihrer Herstellung und pharmazeutische Mittel, die diese Verbindungen enthalten
DE3433327C2 (de) 1-Heteroaryl-4-[(2,5-pyrrolidindion-1-yl)alkyl]piperazinderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
DE60311820T2 (de) Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate
DE3209557C2 (el)
DE3247530A1 (de) Benzisothiazol- und benzisoxazolverbindungen, verfahren zu ihrer herstellung und pharmazeutische mittel, die diese verbindungen enthalten
DE3423898A1 (de) Piperazinyl-alkyl-1,2,4-triazol-3-on-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel
CH663022A5 (de) 1-fluorphenylbutyl-4-(2-pyrimidinyl)piperazin-derivate mit antipsychotischer aktivitaet.
DE1445151A1 (de) Verfahren zur Herstellung chemischer Verbindungen
DE3248138C2 (el)
DE3336024A1 (de) 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
DE60004671T2 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
CH652398A5 (de) Thiazolidindion-derivate, herstellung dieser verbindungen und diese enthaltende pharmazeutische praeparate.
DE3135523C2 (el)
EP0163260B1 (de) Neue substituierte Pyrrolidinone, Verfahren zu ihrer Herstellung und Arzneimittel
AT391698B (de) Verfahren zur herstellung neuer zyklischer imid- derivate von 2-(4-butylpiperazin-1-yl)-pyridinen
EP1176144B1 (de) Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
DE3615180C2 (de) Disubstituierte 1,4-Piperazinylderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
DE3404193C2 (el)
EP0093252B1 (de) Thiomethylpyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3900028A1 (de) Gegebenenfalls am phenylrest halogen- und/oder alkyl- und/oder alkoxy- oder methylendioxysubstituierte, 5,5-di-(methyl)-3-(phenylvinyl)-1-(substituiert amino-alkoxy-imino)-cyclohex-2-enderivate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel
DD298397A5 (de) Verfahren zur herstellung von 1-(heterocyclylsulfonyl-3-/4-(2-pyrimidinyl)-1-piperazinyl/propanen
DE2716838A1 (de) Thioharnstoffderivate
DD219642A5 (de) Verfahren zur herstellung von bis-(piperazinyl- bzw. homopiperazinyl)alkanen
WO2000041697A1 (de) Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie
DE2753878A1 (de) Derivate des 1-(3,5-dichlorphenyl)- piperazins, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition